Rapid Apolipoprotein E ε4 Proteotyping for Alzheimer’s Disease Anti-Amyloid Therapy Eligibility and Risk Assessment
- DOI
- 10.1017/cjn.2026.10688
- Published
- 2026-11-09
- Container
- Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Publisher
- Cambridge University Press (CUP)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1017/cjn.2026.10688,
title = {Rapid Apolipoprotein E ε4 Proteotyping for Alzheimer’s Disease Anti-Amyloid Therapy Eligibility and Risk Assessment},
author = {Yara Alkhodair and Rachael J.Y. Smith and Cyril Helbling and Mari L. DeMarco},
year = {2026},
journal = {Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques},
doi = {10.1017/cjn.2026.10688},
url = {https://doi.org/10.1017/cjn.2026.10688}
}RIS
TY - JOUR TI - Rapid Apolipoprotein E ε4 Proteotyping for Alzheimer’s Disease Anti-Amyloid Therapy Eligibility and Risk Assessment AU - Yara Alkhodair AU - Rachael J.Y. Smith AU - Cyril Helbling AU - Mari L. DeMarco PY - 2026 JO - Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques DO - 10.1017/cjn.2026.10688 UR - https://doi.org/10.1017/cjn.2026.10688 ER -
APA
Alkhodair, Y., Smith, R. J., Helbling, C., & DeMarco, M. L. (2026). Rapid Apolipoprotein E ε4 Proteotyping for Alzheimer’s Disease Anti-Amyloid Therapy Eligibility and Risk Assessment. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/cjn.2026.10688
Source records
- crossref · retrieved 2026-11-10T11:35:01.048Z